S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

OTCMKTS:ZYXI - Zynex Stock Price, Forecast & News

$10.50
+0.32 (+3.14 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$9.93
Now: $10.50
$10.60
50-Day Range
$7.87
MA: $9.88
$10.69
52-Week Range
$4.25
Now: $10.50
$13.10
Volume157,700 shs
Average Volume278,627 shs
Market Capitalization$343.80 million
P/E Ratio47.73
Dividend YieldN/A
Beta1.05
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$0.59 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

EmployeesN/A
Market Cap$343.80 million
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.


Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

How were Zynex's earnings last quarter?

Zynex Inc. (OTCMKTS:ZYXI) announced its quarterly earnings data on Tuesday, October, 29th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.00. The business earned $11.82 million during the quarter, compared to analyst estimates of $11.06 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.

When is Zynex's next earnings date?

Zynex is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Zynex.

What guidance has Zynex issued on next quarter's earnings?

Zynex updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.3-45.8 million, compared to the consensus revenue estimate of $44.11 million.

What price target have analysts set for ZYXI?

2 brokerages have issued 12-month target prices for Zynex's stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Zynex's share price to reach $12.00 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for Zynex.

What is the consensus analysts' recommendation for Zynex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.

Has Zynex been receiving favorable news coverage?

News headlines about ZYXI stock have trended negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zynex earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Zynex.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Who are Zynex's key executives?

Zynex's management team includes the folowing people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
  • Mr. David B. Mogill, VP of Operations
  • Mr. Robert Bird, VP of Marketing
  • Mr. Steve Siefring, Director of Bus. Devel.

Who are Zynex's major shareholders?

Zynex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Punch & Associates Investment Management Inc. (1.64%), State Street Corp (0.99%), Calamos Advisors LLC (0.77%), Cadence Capital Management LLC (0.65%), Russell Investments Group Ltd. (0.56%) and Bank of Montreal Can (0.32%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.

Which institutional investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Calamos Advisors LLC, Toronto Dominion Bank and Credit Suisse AG. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.

Which institutional investors are buying Zynex stock?

ZYXI stock was acquired by a variety of institutional investors in the last quarter, including Punch & Associates Investment Management Inc., Bank of Montreal Can, Russell Investments Group Ltd., Renaissance Technologies LLC, State Street Corp, AQR Capital Management LLC, Bank of New York Mellon Corp and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Zynex.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $10.50.

How big of a company is Zynex?

Zynex has a market capitalization of $343.80 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.

What is Zynex's official website?

The official website for Zynex is http://www.zynexmed.com/.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]


MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel